Immunofoco's IMC002 Shows Promising Results at ASCO GI 2026: Durable Responses in Advanced Gastric Cancer Immunofoco unveiled encouraging results from its IMC002 therapy for advanced gastric cancer at ASCO GI 2026, highlighting a 66.7% response rate.

Immunofoco's IMC002 Shows Promising Results at ASCO GI 2026: Durable Responses in Advanced Gastric Cancer #China #Shanghai #CAR-T_therapy #Immunofoco #IMC002